HRTX - Rasio rega marang prakiraan pendapatan Heron

Heron Therapeutics, Inc. (HRTX) - logo korporat

Can Heron Therapeutics (HRTX) scale its presence in US hospitals? The organization's forward P/S provides the answer, with the current value standing at 0.40. The curve's dynamics help assess the sales growth potential for Zynrelefa and the path to profitability. The successful implementation of treatments for chemotherapy-induced nausea and pain confirms the effectiveness of the struggle for market share within the medical sector.

Heron Therapeutics Inc - Prakiraan rega marang pendapatan HRTX (periode 04.07.2022 - 17.11.2026)

Rincian metrik komprehensif lan analitis Heron Therapeutics Inc (HRTX)

- statistik kapitalisasi pasar:
Analisis umum perusahaan:Heron Therapeutics, Inc. HRTX
Produk sing diprodhuksi Heron

For Heron Therapeutics (HRTX), a forward revenue multiple of 0.40 reflects the market value of the business relative to expected sales volume. This indicator correlates current market capitalization with projected revenue streams, allowing for an assessment of the company's valuation fairness during a period of aggressive market expansion and internal cost optimization.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte Corp. INCY|HUTCHMED Ltd (HCM) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Inhibrx Biosciences Inc INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharmaceuticals FENC|Multiplikator forward rega marang pendapatan NVCT (Nuvectis Pharma, Inc.)|CHRS (Coherus BioSciences) - Rega forward marang dodolan|Corbus Pharmaceuticals - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRDF (Cardiff Oncology Corp)|BeyondSpring Pharma - Multiplikator Forward P/S|Rega forward marang dodolan BCAB (bioatla.com)|LIXT: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Citius Pharma (CTXR)|Rasio rega marang prakiraan pendapatan Cellectar Biosciences, Inc.|BLRX: Rega forward marang dodolan|Multiplikator Forward P/S CANF|Multiplikator Forward P/S Aprea Therapeutics Inc. (APRE)|Rasio rega marang prakiraan pendapatan Kazia Therapeutics Ltd KZIA|SLXN (silexion.com) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Chimerix|CYCC: Multiplikator Forward P/S|Prakiraan rega marang pendapatan G1 Therapeutics Inc. GTHX|Rasio rega marang prakiraan pendapatan Kronos Bio, Inc.|kintara.com (KTRA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ONCT|PRTG (Portage) - Rega forward marang dodolan